MedTrace Logo

A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg

NCT04058873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1980

Last updated 2021-11-05

No results posted yet for this study

Summary

This study intends to build on the previous research and gather data in an actual use study / patient registry of pericoital LNG 1.5mg to understand women's acceptability of the product along with associated side effects, and monitoring for their correct and incorrect use. These findings will contribute to the discussion around the feasibility of pericoital LNG as an additional contraceptive by adding to the body of evidence.

Conditions

  • Pregnancy Related

Interventions

DRUG

Levonorgestrel 1.5mg

Levonorgestrel 1.5mg for pericoital use

Sponsors & Collaborators

  • Population Council

    collaborator OTHER

  • Marie Stopes International

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • The Children's Investment Fund Foundation

    collaborator OTHER

  • Camber Collective

    lead OTHER

Principal Investigators

  • Emmanuel Kuffour · AYA Collective

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-01
Completion
2020-11-01

Countries

  • Ghana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04058873 on ClinicalTrials.gov